Hikma Pharmaceuticals Plc Block Listing Application (2473H)
March 09 2018 - 4:21AM
UK Regulatory
TIDMHIK
RNS Number : 2473H
Hikma Pharmaceuticals Plc
09 March 2018
Block Listing of Shares
Hikma Pharmaceuticals PLC
LONDON, 9 March 2018 - The Board of Hikma Pharmaceuticals PLC
("Hikma") (LSE: HIK) (LEI: 549300BNS685UXH4JI75) (NASDAQ: HIK),
announces that it has made a block listing application to the
Financial Conduct Authority and the London Stock Exchange plc for a
total of 2,000,000 ordinary shares of 10p each in the capital of
the Company to be admitted to the Official List of the UK Listing
Authority. It is expected that admission will be granted on 12
March 2018.
The shares, when issued, will be issued fully paid and rank pari
passu in all respects with the existing issued ordinary shares of
the Company. The shares will be issued pursuant to the vesting of
shares under the Hikma Pharmaceuticals PLC 2009 Management
Incentive Plan and the 2014 Executive Incentive Plan (the "Plans").
Participants in the Plans have or will become entitled to these
shares following the vesting of the shares.
- ENDS -
Enquiries
Hikma Pharmaceuticals
PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical
group focused on developing, manufacturing and marketing a broad
range of both branded and non-branded generic and in-licensed
products. Hikma's operations are conducted through three
businesses: 'Injectables,' 'Generics' and 'Branded,' based
primarily in the Middle East and North Africa (MENA) region, where
it is a market leader, the United States and Europe. In 2016, Hikma
achieved revenues of $1,950 million and profit attributable to
shareholders of $155 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSKKLBBVXFFBBQ
(END) Dow Jones Newswires
March 09, 2018 04:21 ET (09:21 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024